# SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

# **SCHEDULE 13G/A**

Under the Securities Exchange Act of 1934 (Amendment No. 1)\*

# OnKure Therapeutics, Inc. (Name of Issuer)

Common Stock, par value \$0.0001 per share

(Title of Class of Securities)

68277Q105 (CUSIP Number)

October 4, 2024 (Date of Event Which Requires Filing of This Statement)

Check the appropriate box	x to designate the rule pursuant to which this Schedule is filed:
□ Rule 13	d-1(b)
⊠ Rule 13	d-1(c)
□ Rule 13	d-1(d)
	over page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for nt containing information which would alter the disclosures provided in a prior cover page.
	in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Ac wise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the
	Page 1 of 9 pages

CUSIP N	o. 68277Q105		13G	Page 2 of 9 Pages
1	TANG CAPITAL MANA	NOS. OF AB AGEMENT, LL		
2		IATE BOX IF	A MEMBER OF A GROUP*	(a) □ (b) □
3	SEC USE ONLY			
4	CITIZENSHIP OR PLAC DELAWARE	CE OF ORGAN	NIZATION	
EA	NUMBER OF SHARES BENEFICIALLY OWNED BY ACH REPORTING PERSON WITH	7 SO 0 8 SH 294	LE VOTING POWER  ARED VOTING POWER  4,626  LE DISPOSITIVE POWER  ARED DISPOSITIVE POWER	
9	294,626		LLY OWNED BY EACH REPORTING PERSON	
10			MOUNT IN ROW (9) EXCLUDES CERTAIN SHA	.RES
11	PERCENT OF CLASS R 2.3%	EPRESENTEI	D BY AMOUNT IN ROW 9	
12	TYPE OF REPORTING	PERSON		

Page 2 of 9 pages

	o. 68277Q105		13G	Page 3 of 9 Pages	
1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)				
	KEVIN TANG				
2	CHECK THE APPROPRI	ATE BOX 1	F A MEMBER OF A GROUP*	(a) □ (b) □	
3	SEC USE ONLY				
4	CITIZENSHIP OR PLAC	E OF ORGA	ANIZATION		
	UNITED STATES	la la	OLE MOTING BOWER		
	NUMBER OF SHARES	3	OLE VOTING POWER  HARED VOTING POWER		
	BENEFICIALLY OWNED BY	2	94,626		
	ACH REPORTING PERSON WITH	,	OLE DISPOSITIVE POWER		
		O	HARED DISPOSITIVE POWER 94,626		
9	AGGREGATE AMOUNT 294,626		ALLY OWNED BY EACH REPORTING PERSON		
10		GREGATE	AMOUNT IN ROW (9) EXCLUDES CERTAIN SHA	ARES	
11	PERCENT OF CLASS RE	EPRESENT	ED BY AMOUNT IN ROW 9		
12	TYPE OF REPORTING P	ERSON			
	IN				

Page 3 of 9 pages

CUSIP N	o. 68277Q105		13G	Page 4 of 9 Pages
1	NAMES OF REPORTING I.R.S. IDENTIFICATION TANG CAPITAL PARTN	NOS. OF AB	OVE PERSONS (ENTITIES ONLY)	
2	CHECK THE APPROPRI	ATE BOX IF	A MEMBER OF A GROUP*	(a) □ (b) □
3	SEC USE ONLY			
4	CITIZENSHIP OR PLAC DELAWARE	E OF ORGAN	NIZATION	
EA	NUMBER OF SHARES BENEFICIALLY OWNED BY ACH REPORTING PERSON WITH	7 SO 0 8 SH 294 7 SO 0 8 SH 294	LE VOTING POWER  ARED VOTING POWER  4,626  LE DISPOSITIVE POWER  ARED DISPOSITIVE POWER	
9	294,626		LLY OWNED BY EACH REPORTING PERSON	
10			MOUNT IN ROW (9) EXCLUDES CERTAIN SHA	ARES
11	PERCENT OF CLASS RI 2.3%	EPRESENTEI	D BY AMOUNT IN ROW 9	
12	TYPE OF REPORTING F	PERSON		

Page 4 of 9 pages

CUSIP No	o. 68277Q105		13G	Page 5 of 9 Pages
1	NAMES OF REPORTING I.R.S. IDENTIFICATION CONCENTRA BIOSCIEN	NOS. OF AB	OVE PERSONS (ENTITIES ONLY)	
2			A MEMBER OF A GROUP*	(a) □ (b) □
3	SEC USE ONLY			
4	CITIZENSHIP OR PLACE	E OF ORGAN	NIZATION	
EA	NUMBER OF SHARES BENEFICIALLY OWNED BY ACH REPORTING PERSON WITH	7 SO 0 8 SH 0	LE VOTING POWER  ARED VOTING POWER  LE DISPOSITIVE POWER  ARED DISPOSITIVE POWER	
9	0		LLY OWNED BY EACH REPORTING PERSON	
10			MOUNT IN ROW (9) EXCLUDES CERTAIN SHA	ARES
11	PERCENT OF CLASS RE	EPRESENTEI	D BY AMOUNT IN ROW 9	
12	TYPE OF REPORTING P	ERSON		

Page 5 of 9 pages

Item 1(a). Name of Issuer:

OnKure Therapeutics, Inc., a Delaware corporation, formerly known as Reneo Pharmaceuticals, Inc. (the "Issuer")

**Item 1(b).** Address of Issuer's Principal Executive Offices:

6707 Winchester Circle, Suite 400, Boulder, CO 80301

Item 2(a). Name of Person Filing:

This Statement on Schedule 13G (this "Statement") is filed by Tang Capital Management, LLC, the general partner of Tang Capital Partners, LP ("Tang Capital Management"); Kevin Tang, the manager of Tang Capital Management and the Chief Executive Officer of Concentra Biosciences, LLC; Tang Capital Partners, LP ("Tang Capital Partners"); and Concentra Biosciences, LLC, an affiliate of Tang Capital Partners ("Concentra").

**Item 2(b).** Address of Principal Business Office or, if none, Residence:

4747 Executive Drive, Suite 210, San Diego, CA 92121

Item 2(c). Citizenship:

Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen. Tang Capital Partners is a Delaware limited partnership. Concentra is a Delaware limited liability company.

**Item 2(d).** Title of Class of Securities:

Common Stock, par value \$0.0001 per share

Item 2(e). CUSIP Number 68277Q105

Item 3. Not applicable.

Item 4. Ownership.

(a) Amount Beneficially Owned:

Tang Capital Management. Tang Capital Management beneficially owns 294,626 shares of the Issuer's Common Stock.

Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang.

Kevin Tang. Kevin Tang beneficially owns 294,626 shares of the Issuer's Common Stock.

Page 6 of 9 pages

Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners and Tang Capital Management.

Tang Capital Partners. Tang Capital Partners beneficially owns 294,626 shares of the Issuer's Common Stock.

Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

The percentages used herein are based on 12,652,811 shares of Common Stock outstanding as of October 4, 2024, as set forth in the Issuer's Current Report filed on Form 8-K that was filed with the Securities and Exchange Commission on October 8, 2024.

#### (b) Percent of Class:

Tang Capital Management	2.3%
Kevin Tang	2.3%
Tang Capital Partners	2.3%
Concentra	0.0%

- (c) Number of shares as to which such person has:
  - (i) sole power to vote or to direct the vote:

0 shares
0 shares
0 shares
0 shares

(ii) shared power to vote or to direct the vote:

Tang Capital Management	294,626 shares
Kevin Tang	294,626 shares
Tang Capital Partners	294,626 shares
Concentra	0 shares

(iii) sole power to dispose or to direct the disposition of:

Tang Capital Management0 sharesKevin Tang0 sharesTang Capital Partners0 sharesConcentra0 shares

(iv) shared power to dispose or to direct the disposition of:

Tang Capital Management294,626 sharesKevin Tang294,626 sharesTang Capital Partners294,626 sharesConcentra0 shares

## Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:

## Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable

## Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

Not applicable.

## Item 8. Identification and Classification of Members of the Group.

Not applicable.

#### Item 9. Notice of Dissolution of Group.

Not applicable.

#### Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Page 8 of 9 pages

## SIGNATURE

After re	easonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct
Date: ]	November 14, 2024
TANG	CAPITAL PARTNERS, LP
By: Tai	ng Capital Management, LLC, its General Partner
By:	/s/ Kevin Tang Kevin Tang, Manager
TANG	CAPITAL MANAGEMENT, LLC
Ву: _	/s/ Kevin Tang Kevin Tang, Manager
	in Tang
Kevin	Tang
CONC	ENTRA BIOSCIENCES, LLC
Ву:	/s/ Kevin Tang Kevin Tang, Chief Executive Officer
	Page 9 of 9 Pages